Last reviewed · How we verify
NCT05379426
Older Adults' Perceptions of the Impact COVID-19 Pandemic
trial testing Impact COVID-19 pandemic in COVID-19 Pandemic in 880 participants. Completed in 31 July 2022.
31 July 2022
Quick facts
| Lead sponsor | Rsocialform - Geriatria, Lda |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 880 |
| Start date | 1 June 2022 |
| Primary completion | 31 July 2022 |
| Estimated completion | 31 July 2022 |
| Sites | 58 locations across Portugal |
Drugs / interventions tested
- Impact COVID-19 pandemic
Conditions studied
- COVID-19 Pandemic — all drugs for COVID-19 Pandemic →
- Depression, Anxiety — all drugs for Depression, Anxiety →
- Cognitive Impairment — all drugs for Cognitive Impairment →
- Quality of Life — all drugs for Quality of Life →
Sponsor
Rsocialform - Geriatria, Lda
Who can join
65 and older, any sex, with COVID-19 Pandemic or Depression, Anxiety. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This multicentre study will be conduct in several Portuguese institutions, which provide care and supporting services for older adults, with aim to assess the impact of COVID-19 pandemic on the cognitive, emotional and social status of their beneficiaries. Initially, data on global cognitive function, executive function, mood, anxiety, loneliness, and quality of life will be collected. Secondly, a semi-structured interview will be carried out to realize and understand what were the major difficulties experienced by the older adult during the pandemic period.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05379426
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19 Pandemic
Currently open trials in the same condition.
- NCT05825651 — Long COVID and Its Associations With Health Outcomes in Older Adults · active not recruiting
- NCT06927622 — Corona Virus Disease 2019 Cohort Study · recruiting
- NCT05096260 — Getting to Yes, Michigan! (G2YMI) · NA · active not recruiting
- NCT06208943 — Neural and Cognitive Consequences of COVID-19 Survival · recruiting
Other Rsocialform - Geriatria, Lda trials
Trials by the same sponsor.
- NCT07041008 — Cognitive Stimulation in Older Adults With Alzheimer's Disease · NA · completed
- NCT06812442 — Effectiveness of a 3-month Individual Reminiscence Therapy Program in Older Adults With Alzheimer's Disease · NA · completed
- NCT05433493 — Effect of Individual Cognitive Stimulation on Memory and Executive Function in Older Adults With Alzheimer's Disease · NA · completed
- NCT04658394 — Effect of Individual Reminiscence Therapy in the Elderly People With Neurocognitive Disorders · NA · completed
- NCT04180683 — Comparison Study of the Different Abbreviated Versions of the Geriatric Depression Scale · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05379426 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Rsocialform - Geriatria, Lda
- Last refreshed: 2 August 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05379426.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing